![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-demecolcine | decreases expression | ISO | RGD:1346519 | 6480464 | Demecolcine results in decreased expression of GNL3L mRNA | CTD | PMID:23649840 | 1,2-dimethylhydrazine | decreases expression | ISO | RGD:1619824 | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of GNL3L mRNA | CTD | PMID:22206623 | 1,4-dichlorobenzene | increases expression | ISO | RGD:1619824 | 6480464 | 4-dichlorobenzene results in increased expression of GNL3L mRNA | CTD | PMID:26975756 | 17beta-estradiol | decreases expression | ISO | RGD:1346519 | 6480464 | Estradiol results in decreased expression of GNL3L mRNA | CTD | PMID:20106945, PMID:21632981 | 17beta-estradiol | increases expression | ISO | RGD:1346519 | 6480464 | Estradiol results in increased expression of GNL3L mRNA | CTD | PMID:23019147 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1619824 | 6480464 | Tetrachlorodibenzodioxin affects the expression of GNL3L mRNA | CTD | PMID:21570461 | 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2, 4-dinitrotoluene affects the expression of GNL3L mRNA | CTD | PMID:21346803 | 3,4-methylenedioxymethamphetamine | increases expression | ISO | RGD:1619824 | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in increased expression of GNL3L mRNA | CTD | PMID:20188158 | 3,4-methylenedioxymethamphetamine | decreases expression | ISO | RGD:1619824 | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of GNL3L mRNA | CTD | PMID:26251327 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:1346519 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of GNL3L mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of GNL3L mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | RGD:1346519 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of GNL3L mRNA | CTD | PMID:28628672 | 4-amino-2,6-dinitrotoluene | affects expression | EXP | | 6480464 | 4-amino-2, 6-dinitrotoluene affects the expression of GNL3L mRNA | CTD | PMID:21346803 | acetamide | decreases expression | EXP | | 6480464 | acetamide results in decreased expression of GNL3L mRNA | CTD | PMID:31881176 | amphetamine | decreases expression | EXP | | 6480464 | Amphetamine results in decreased expression of GNL3L mRNA | CTD | PMID:30779732 | antirheumatic drug | decreases expression | ISO | RGD:1346519 | 6480464 | Antirheumatic Agents results in decreased expression of GNL3L mRNA | CTD | PMID:24449571 | atrazine | decreases expression | ISO | RGD:1346519 | 6480464 | Atrazine results in decreased expression of GNL3L mRNA | CTD | PMID:22378314 | benzo[a]pyrene | increases expression | ISO | RGD:1619824 | 6480464 | Benzoapyrene results in increased expression of GNL3L mRNA | CTD | PMID:22228805 | benzo[a]pyrene | increases expression | ISO | RGD:1346519 | 6480464 | Benzoapyrene results in increased expression of GNL3L mRNA | CTD | PMID:32234424 | benzo[a]pyrene | increases methylation | ISO | RGD:1346519 | 6480464 | Benzoapyrene results in increased methylation of GNL3L exon | CTD | PMID:27901495 | benzo[a]pyrene | affects methylation | ISO | RGD:1346519 | 6480464 | Benzoapyrene affects the methylation of GNL3L 5' UTR, Benzoapyrene affects the methylation of GNL3L promoter | CTD | PMID:27901495 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RGD:1346519 | 6480464 | 7 more ... | CTD | PMID:20018196, PMID:26238291 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of GNL3L mRNA | CTD | PMID:25181051, PMID:30816183 | bisphenol F | multiple interactions | ISO | RGD:1346519 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of GNL3L mRNA | CTD | PMID:28628672 | cisplatin | multiple interactions | ISO | RGD:1346519 | 6480464 | [Cisplatin co-treated with panobinostat] affects the expression of GNL3L mRNA | CTD | PMID:21791302 | cisplatin | decreases expression | ISO | RGD:1346519 | 6480464 | Cisplatin results in decreased expression of GNL3L mRNA | CTD | PMID:27594783 | cobalt dichloride | decreases expression | ISO | RGD:1346519 | 6480464 | cobaltous chloride results in decreased expression of GNL3L mRNA | CTD | PMID:19320972 | coumestrol | decreases expression | ISO | RGD:1346519 | 6480464 | Coumestrol results in decreased expression of GNL3L mRNA | CTD | PMID:19167446 | dexamethasone | multiple interactions | ISO | RGD:1346519 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of GNL3L mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of GNL3L mRNA | CTD | PMID:28628672 | diazinon | increases methylation | ISO | RGD:1346519 | 6480464 | Diazinon results in increased methylation of GNL3L gene | CTD | PMID:22964155 | dicrotophos | increases expression | ISO | RGD:1346519 | 6480464 | dicrotophos results in increased expression of GNL3L mRNA | CTD | PMID:28302478 | dorsomorphin | multiple interactions | ISO | RGD:1346519 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of GNL3L mRNA | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:1346519 | 6480464 | Doxorubicin results in decreased expression of GNL3L mRNA | CTD | PMID:29803840 | ethanol | affects splicing | ISO | RGD:1619824 | 6480464 | Ethanol affects the splicing of GNL3L mRNA | CTD | PMID:30319688 | ethyl methanesulfonate | decreases expression | ISO | RGD:1346519 | 6480464 | Ethyl Methanesulfonate results in decreased expression of GNL3L mRNA | CTD | PMID:23649840 | finasteride | increases expression | EXP | | 6480464 | Finasteride results in increased expression of GNL3L mRNA | CTD | PMID:24136188 | flutamide | increases expression | EXP | | 6480464 | Flutamide results in increased expression of GNL3L mRNA | CTD | PMID:24136188 | flutamide | decreases expression | EXP | | 6480464 | Flutamide results in decreased expression of GNL3L mRNA | CTD | PMID:24793618 | folic acid | decreases expression | ISO | RGD:1619824 | 6480464 | Folic Acid results in decreased expression of GNL3L mRNA | CTD | PMID:25629700 | formaldehyde | decreases expression | ISO | RGD:1346519 | 6480464 | Formaldehyde results in decreased expression of GNL3L mRNA | CTD | PMID:23649840 | indometacin | multiple interactions | ISO | RGD:1346519 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of GNL3L mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of GNL3L mRNA | CTD | PMID:28628672 | methapyrilene | decreases expression | EXP | | 6480464 | Methapyrilene results in decreased expression of GNL3L mRNA | CTD | PMID:30467583 | methyl methanesulfonate | decreases expression | ISO | RGD:1346519 | 6480464 | Methyl Methanesulfonate results in decreased expression of GNL3L mRNA | CTD | PMID:23649840 | nefazodone | increases expression | EXP | | 6480464 | nefazodone results in increased expression of GNL3L mRNA | CTD | PMID:24136188 | nickel atom | increases expression | ISO | RGD:1346519 | 6480464 | Nickel results in increased expression of GNL3L mRNA | CTD | PMID:24768652, PMID:25583101 | panobinostat | multiple interactions | ISO | RGD:1346519 | 6480464 | [Cisplatin co-treated with panobinostat] affects the expression of GNL3L mRNA | CTD | PMID:21791302 | paracetamol | increases expression | ISO | RGD:1346519 | 6480464 | Acetaminophen results in increased expression of GNL3L mRNA | CTD | PMID:26690555 | SB 431542 | multiple interactions | ISO | RGD:1346519 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of GNL3L mRNA | CTD | PMID:27188386 | silicon dioxide | decreases expression | ISO | RGD:1346519 | 6480464 | Silicon Dioxide analog results in decreased expression of GNL3L mRNA | CTD | PMID:23806026 | sulindac | decreases expression | EXP | | 6480464 | Sulindac results in decreased expression of GNL3L mRNA | CTD | PMID:24136188 | sunitinib | decreases expression | ISO | RGD:1346519 | 6480464 | Sunitinib results in decreased expression of GNL3L mRNA | CTD | PMID:31533062 | testosterone enanthate | affects expression | ISO | RGD:1346519 | 6480464 | testosterone enanthate affects the expression of GNL3L mRNA | CTD | PMID:17440010 | tetrachloromethane | increases expression | ISO | RGD:1619824 | 6480464 | Carbon Tetrachloride results in increased expression of GNL3L mRNA | CTD | PMID:27339419, PMID:31919559 | thapsigargin | increases expression | ISO | RGD:1346519 | 6480464 | Thapsigargin results in increased expression of GNL3L mRNA | CTD | PMID:22378314 | trichostatin A | increases expression | ISO | RGD:1346519 | 6480464 | trichostatin A results in increased expression of GNL3L mRNA | CTD | PMID:26272509 | trichostatin A | multiple interactions | ISO | RGD:1346519 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of GNL3L mRNA | CTD | PMID:27188386 | triptonide | decreases expression | ISO | RGD:1619824 | 6480464 | triptonide results in decreased expression of GNL3L mRNA | CTD | PMID:33045310 | tungsten | decreases expression | ISO | RGD:1619824 | 6480464 | Tungsten results in decreased expression of GNL3L mRNA | CTD | PMID:30912803 | tunicamycin | increases expression | ISO | RGD:1346519 | 6480464 | Tunicamycin results in increased expression of GNL3L mRNA | CTD | PMID:22378314 | valproic acid | affects expression | ISO | RGD:1619824 | 6480464 | Valproic Acid affects the expression of GNL3L mRNA | CTD | PMID:17292431 | valproic acid | decreases expression | ISO | RGD:1346519 | 6480464 | Valproic Acid results in decreased expression of GNL3L mRNA | CTD | PMID:23527032 | valproic acid | affects expression | ISO | RGD:1346519 | 6480464 | Valproic Acid affects the expression of GNL3L mRNA | CTD | PMID:25979313 | vinclozolin | increases expression | EXP | | 6480464 | vinclozolin results in increased expression of GNL3L mRNA | CTD | PMID:23034163 | |